AI assistant
Anteris Technologies Global Corp. — Capital/Financing Update 2016
Jul 28, 2016
33869_rns_2016-07-28_c2b6e162-b4f7-4cf4-8fb8-a2ad92a84a30.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [226 x 82] intentionally omitted <==
Admedus Ltd ABN 35 088 221 078
REGISTERED OFFICE: 26 Harris Road Malaga Western Australia 6090
ASX ANNOUNCEMENT
PO Box 6879 East Perth Western Australia 6892 T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E [email protected]
ADMEDUS ANNOUNCES PLACEMENT & RIGHTS ISSUE OF $18.3M
-
Oversubscribed placement for $10M
-
1:9 renounceable rights issue to existing shareholders to raise a further $8.3M
-
Capital places the Company in a strong financial position
-
Targeting sustainable profitability in FY18
Brisbane, Australia 29 July 2016
Admedus Limited (the Company) (ASX: AHZ) is pleased to announce that it has secured firm commitments for a oversubscribed $10M private placement of ordinary shares to new institutional and existing and sophisticated investors at an issue price of $0.33.
The Company will also undertake a 1:9 renounceable rights issue of ordinary shares at an issue price of $0.33 to raise a total of $18.3M (before costs). Shareholders on the register at 5pm (WST) on 15 August 2016 will be entitled to participate in the rights issue. More information regarding the rights issue will be set out in the Prospectus, to be mailed to eligible shareholders in accordance with the timeline below. Patersons Securities Limited acted as Lead Manager to the Offer.
Admedus Chairman and Interim CEO, Mr Wayne Paterson, commented: “This capital raise will allow us to continue our current strong sales growth and roll-out additional products into the cardiovascular markets, whilst implementing our corporate strategy of tighter expenditure control. The completion of this capital raise, in addition to the implementation of our recent strategic review, removes any concerns about the finances of Admedus and places the Company in a very strong position to achieve sustainable profitability for the 2018 financial year (if not before) and beyond. ”
Admedus will use the funds raised from the placement and the rights issue to execute its recently announced corporate restructuring with the majority allocated for working capital. In addition, funds will be used for the purposes of:
-
Scale up of manufacturing to meet market demand;
-
New product and IP development;
-
New market expansion across emerging markets and new product ranges;
-
Further investment and development in immunotherapy programmes in conjunction with Professor Ian Frazer; and
-
Clinical and post market studies.
The indicative timetable for the rights issue is set out below. Please note that this timetable is indicative only. The Company reserves the right to amend this indicative timetable at any time, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules.
==> picture [595 x 44] intentionally omitted <==
==> picture [170 x 63] intentionally omitted <==
Option holders should note that in order to be able to participate in the rights issue they will need to exercise their options. Further details will be provided to option holders shortly.
- Subject to the ASX Listing Rules, the Directors reserve the right to extend the Closing Date for the rights issue at their discretion. Should this occur, the extension will have a
| Event | Date |
|---|---|
| 'Ex' Date (Date from which shares commence trading without the | 12 August |
| entitlement to participate in the rights issue) | 2016 |
| Record Date at 5.00pm WST (Date for determining entitlements of | 15 August |
| eligible shareholder to participate in the rights issue) | 2016 |
| Prospectus dispatched to eligible shareholders | 18 August |
| 2016 | |
| Opening Date | 18 August |
| 2016 | |
| Closing Date at 3.00pm WST* | 29 of August |
| 2016 | |
| Issue Date ( Allocation of new shares) | 5 September |
| 2016 |
consequential effect on the anticipated date of issue for the new shares.
Follow us:
Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com Blog: www.admedus.com/au/category/news/
For more information, please contact:
Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100
Media :
Shevaun Cooper | PR Manager | Admedus Limited Tel: +61 (0) 417 985 599 | Email: [email protected]
Media Europe
FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000 [email protected]
US Investor
Rx Communications Group, LLC Melody A. Carey +1 917 322 2571 [email protected]
==> picture [170 x 63] intentionally omitted <==
About Admedus Limited
Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com